NCT03578185 — Samsung Medical Center cancer immunotherapy trial
Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy
Registry record
| Registry ID | NCT03578185 ↗ |
|---|---|
| Lead sponsor | Samsung Medical Center |
| Collaborators | — |
| Phase | — |
| Status | Recruiting |
| Indication | Lung Cancer |
| Enrollment | 2,000 participants (target) |
| Start date | 2018-04-11 |
| Primary completion | 2030-12-31 (est.) |
| Last registry update | 12 Aug 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT03578185), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
FAQ
What phase is NCT03578185?
NCT03578185 (Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy) is registered on ClinicalTrials.gov as having no assigned phase, sponsored by Samsung Medical Center.
Is NCT03578185 recruiting?
As of the 2026-08-12 registry update, NCT03578185 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT03578185?
The lead sponsor is Samsung Medical Center.
What condition does NCT03578185 study?
The registered condition is Lung Cancer. Primary completion is listed as 2030-12-31 (estimated).
Are results available for NCT03578185?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT03578185.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.